Olanzapine

Generic Name
Olanzapine
Brand Names
Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
Drug Type
Small Molecule
Chemical Formula
C17H20N4S
CAS Number
132539-06-1
Unique Ingredient Identifier
N7U69T4SZR
Background

Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...

Indication

Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...

Associated Conditions
Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
Associated Therapies
-
Clinical Trials
Related News

40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)

Phase 3
Completed
Conditions
Bipolar Disorder
Interventions
Drug: asenapine
Drug: Olanzapine
First Posted Date
2005-09-12
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
218
Registration Number
NCT00159783

3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)

First Posted Date
2005-09-12
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
488
Registration Number
NCT00159744

3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)

First Posted Date
2005-09-12
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
489
Registration Number
NCT00159796

Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: asenapine
Drug: Placebo
Drug: olanzapine
First Posted Date
2005-09-12
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
417
Registration Number
NCT00156117

Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: asenapine
Drug: Olanzapine
Drug: Placebo
First Posted Date
2005-09-09
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
277
Registration Number
NCT00151424

Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo

Phase 2
Completed
Conditions
Schizophrenia
Interventions
Drug: placebo
Drug: LY2140023
Drug: olanzapine
First Posted Date
2005-09-08
Last Posted Date
2021-08-20
Lead Sponsor
Denovo Biopharma LLC
Target Recruit Count
195
Registration Number
NCT00149292
Locations
🇷🇺

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Village Nikolskoe, Russian Federation

A First In Human Study Of PF-00184562 In Healthy Volunteers

Phase 1
Completed
Conditions
Schizophrenia
First Posted Date
2005-09-08
Last Posted Date
2006-07-25
Lead Sponsor
Pfizer
Target Recruit Count
18
Registration Number
NCT00150215
Locations
🇺🇸

Pfizer Investigational Site, Austin, Texas, United States

Energy Homeostasis Under Treatment With Atypical Antipsychotics

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: olanzapine
Drug: Ziprasidone
First Posted Date
2005-09-08
Last Posted Date
2008-09-29
Lead Sponsor
Charite University, Berlin, Germany
Target Recruit Count
40
Registration Number
NCT00148564
Locations
🇩🇪

Charité Universitaetsmedizin Berlin; Campus Charité Mitte; Dept. for Psychiatry and Psychotherapy, Berlin, Germany

Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: Asenapine
Drug: Olanzapine
First Posted Date
2005-09-05
Last Posted Date
2022-02-08
Lead Sponsor
Organon and Co
Target Recruit Count
468
Registration Number
NCT00145496

Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study

Phase 3
Completed
Conditions
Schizophrenia
Psychotic Disorders
First Posted Date
2005-09-05
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
100
Registration Number
NCT00145444
Locations
🇳🇱

Pfizer Investigational Site, Utrecht, Netherlands

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy